Miniatura

Fitxers

journal.pone.0261711.pdf (478.59 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-01-21

Llicència de publicació

cc by (c) Lavilla Olleros, Cristina et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/187043

Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1371/journal.pone.0261711

Resum

Objective To describe the impact of different doses of corticosteroids on the evolution of patients with COVID-19 pneumonia, based on the potential benefit of the non-genomic mechanism of these drugs at higher doses. Methods Observational study using data collected from the SEMI-COVID-19 Registry. We evaluated the epidemiological, radiological and analytical scenario between patients treated with megadoses therapy of corticosteroids vs low-dose of corticosteroids and the development of complications. The primary endpoint was all-cause in-hospital mortality according to use of corticosteroids megadoses. Results Of a total of 14,921 patients, corticosteroids were used in 5,262 (35.3%). Of them, 2,216 (46%) specifically received megadoses. Age was a factor that differed between those who received megadoses therapy versus those who did not in a significant manner (69 years [IQR 59-79] vs 73 years [IQR 61-83]; p < .001). Radiological and analytical findings showed a higher use of megadoses therapy among patients with an interstitial infiltrate and elevated inflammatory markers associated with COVID-19. In the univariate study it appears that steroid use is associated with increased mortality (OR 2.07 95% CI 1.91-2.24 p < .001) and megadose use with increased survival (OR 0.84 95% CI 0.75-0.96, p 0.011), but when adjusting for possible confounding factors, it is observed that the use of megadoses is also associated with higher mortality (OR 1.54, 95% CI 1.32-1.80; p < .001). There is no difference between megadoses and low-dose (p.298). Although, there are differences in the use of megadoses versus low-dose in terms of complications, mainly infectious, with fewer pneumonias and sepsis in the megadoses group (OR 0.82 95% CI 0.71-0.95; p < .001 and OR 0.80 95% CI 0.65-0.97; p < .001) respectively. Conclusion There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses.

Matèries

COVID-19, SARS-CoV-2, Epidemiologia, Corticosteroides

Matèries (anglès)

COVID-19, SARS-CoV-2, Epidemiology, Adrenocortical hormones

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

LAVILLA OLLEROS, Cristina, AUSÍN GARCÍA, Cristina, BENDALA ESTRADA, Alejandro david, MUÑOZ, Ana, WIKMAN JOGERSEN, Philip erick, FERNÁNDEZ CRUZ, Ana, GINER GALVAÑ, Vicente, VARGAS, Juan antonio, SEGUÍ RIPOLL, José miguel, RUBIO RIVAS, Manuel, MIRANDA GODOY, Rodrigo, MÉRIDA RODRIGO, Luis, FONSECA AIZPURU, Eva, ARNALICH FERNÁNDEZ, Francisco, ARTERO, Arturo, LOUREIRO AMIGO, Jose, GARCÍA GARCÍA, Gema maría, CORRAL GUDINO, Luis, JIMÉNEZ TORRES, Jose, CASAS ROJO, José manuel, MILLÁN NÚÑEZ-CORTÉS, Jesús, On Behalf of the SEMI-COVID-19 Network. Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19. _PLOS ONE_. 2022. Vol. 17, núm. 1, pàgs. e0261711. [consulta: 13 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/187043]

Exportar metadades

JSON - METS

Compartir registre